Acelyrin (SLRN) versus Its Rivals Head to Head Review

Acelyrin (NASDAQ:SLRN) is one of 992 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Acelyrin to similar companies based on the strength of its earnings, profitability, institutional ownership, analyst recommendations, dividends, valuation and risk.

Profitability

This table compares Acelyrin and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acelyrin	N/A	-50.56%	-38.65%
Acelyrin Competitors	-2,580.20%	-256.50%	-30.52%

Analyst Recommendations

This is a breakdown of recent ratings for Acelyrin and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acelyrin	0	3	4	0	2.57
Acelyrin Competitors	6344	18663	44310	912	2.57

Acelyrin currently has a consensus price target of $23.67, indicating a potential upside of 444.06%. As a group, “Pharmaceutical preparations” companies have a potential upside of 77.23%. Given Acelyrin’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Acelyrin is more favorable than its competitors.

Valuation and Earnings

This table compares Acelyrin and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Acelyrin	N/A	-$381.64 million	-0.41
Acelyrin Competitors	$1.70 billion	$149.62 million	-3.45

Acelyrin’s competitors have higher revenue and earnings than Acelyrin. Acelyrin is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

87.3% of Acelyrin shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.3% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Acelyrin Company Profile

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.